oral ROR_t inverse agonist

Ph. I in HV up to 200 mg w/ PD, discontinued

from HTS + opt.

Scientific Reports, May 26, 2021

Janssen R&D, La Jolla, CA


The Janssen RORgt inhibitor, JNJ-61803534, is an oral clinical candidate that was well-tolerated in humans up to 200 mg and demonstrated PD. Unfortunately, development was terminated due to findings in…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: